亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

成都云希化工有限公司  

美容肽,多肽,美容原料,定制肽,醫藥中間體

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:陳
  • 電話:19150309904
  • 郵件:aileen@youngshechem.com
  • 微信:19150309904
  • QQ:1398029096
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 棕櫚酰二肽-7Palmitoyl Dipeptide-7
棕櫚酰二肽-7Palmitoyl Dipeptide-7
單價 10.00 / g對比
銷量 暫無
發貨 四川成都市付款后3天內
庫存 10000g起訂1g
品牌 成都云希
CAS號 911813-90-6
分子式 C26H51N3O5
分子量 485.7
過期 長期有效
更新 2021-07-05 16:42
 
詳細信息

1.Basic information:

INCI Name: Palmitoyl Dipeptide-7

Reference: palestrina

Cas No: 911813-90-6

Formula: C26H51N3O5

Molecular:485.7

Purity: >95%

Grade: cosmetic

Source: synthetic

Formulation: available for your reference

Delivery: promptly from stock

Capacity: 1kg per month

Appearance: white powder

 

2.Description: Palmitoyl Dipeptide-7 is one of the shortest peptides. When tested with human skin equivalents, it was found to enhance differentiation of the epidermis, basement membrane zone,and dermal fibroblasts. Within dermal fibroblasts, Palmitoyl Dipeptide-7 increased collagen I, collagen IV,and fibronectin. Use of peptides for topical application is limited by the ionic nature of the amino acid chains.However, this may be circumvented through the incorporation of a lipophilic derivative, such as palmitoyl.

 

©2025 成都云希化工有限公司 版權所有   技術支持:化工網   訪問量:41521  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |